e-Drug3D

2136

M TREOSULFAN

INN
TREOSULFAN

cas 30031-63-1

CLASS

ANTINEOPLASTIC
ALKYLATING DRUG
FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT)
ACUTE MYELOID LEUKEMIA (AML)
MYELODYSPLASTIC SYNDROME (MDS)

ROUTE (list)

ATC code

L01AB02

PK parameters

Target

TARGET DNA

DrugCentral

Download SDF file

(2S,3S)-1,2-Epoxy-3,4-butanediol 4-methanesulfonate

Formula:
C5H10O5S

Calculated chemical properties:

MW 182.20
NB_atoms 11
XLogP -1.28
PSA 78.652
NB_HD 1
NB_HA 5
fsp3 1.00
Lipinski(0=no;1=yes) 1

FDA
-

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL

e-Drug3D

2120

TREOSULFAN

INN
TREOSULFAN

(has an active metabolite)

cas 299-75-2

CLASS

ANTINEOPLASTIC
ALKYLATING DRUG
FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT)
ACUTE MYELOID LEUKEMIA (AML)
MYELODYSPLASTIC SYNDROME (MDS)

ROUTE (list)

INTRAVENOUS

ATC code

L01AB02

PK parameters

VD 41 LITER
PPB 0 PERCENT
t1/2 1.7 HOUR

Solubility

SOLUBLE IN WATER

Target

TARGET DNA

DrugCentral

Unknown

Download SDF file

1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, (2S,3S)-

Formula:
C6H14O8S2

Calculated chemical properties:

MW 278.31
NB_atoms 16
XLogP -2.34
PSA 127.444
NB_HD 2
NB_HA 8
fsp3 1.00
Lipinski(0=no;1=yes) 1

FDA
NDA 214759 (label) INN (TREOSULFAN) GRAFAPEX (MEDEXUS) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY